ECL · Q1 2026 Earnings

Bullish

Ecolab

Reported April 28, 2026

30-second summary

Ecolab delivered $1.70 adjusted EPS at the top of the $1.67–$1.73 guide (+13% YoY) on $4.07B revenue (+10% reported, +4.0% organic), with adjusted OI margin of 16.7% (+70bps YoY) and adjusted OI growth of 15%. The actual news is the FY2026 reset: reported sales growth raised to 9–11% (from 7–9%), organic growth outlook lifted with explicit H2 acceleration to 6–7% (from a 3–4% FY band), and the operating margin language shifted from "100–150bps expansion" to an absolute "~19%" target — three concurrent raises on the same print. CoolIT growth disclosed as approaching triple digits (vs. the 30%+ initial frame), Life Sciences bioprocessing more than doubled, and management committed to fully offsetting the 9% commodity cost impact via an energy surcharge by Q2 exit.

Headline numbers

EPS

Q1 FY2026

$1.70

Revenue

Q1 FY2026

$4.07B

+10.0% YoY

Gross margin

Q1 FY2026

43.8%

Operating margin

Q1 FY2026

16.7%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$4.07B	+10.0%	$4.20B	-3.1%
EPS	$1.70	—	$2.08	-18.3%
Gross margin	43.8%	—	44.1%	-30bps
Operating margin	16.7%	—	18.5%	-180bps

Guidance

Ecolab raised FY2026 reported sales growth guidance to 9–11% from 7–9%, increased organic growth outlook with H2 acceleration to 6–7%, and confirmed 12–15% adjusted EPS growth, signaling strong momentum post-Ovivo and confidence in pricing-driven acceleration.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Diluted EPS	Q1 FY2026	$1.67 to $1.73 (+11% to 15% YoY)	$1.70	at high end of guide; +11.8% YoY (within upper bound of +11% to 15%)	Beat

New guidance

Metric	Period	Guide	YoY
Adjusted Diluted EPS	Q2 FY2026	$2.02 to $2.12 (+7% to 12% YoY)	+7% to 12%

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Reported Sales Growth	FY2026	7% to 9%	9% to 11%	+2 percentage points at both the low and high end	Raised
Organic Sales Growth	FY2026	3% to 4%	accelerating through year; 6% to 7% in H2	Midpoint raised from 3.5% to implied ~5–5.5% for full year; H2 explicitly guided 6–7%	Raised
Adjusted Operating Income Margin	FY2026	~100 to 150 basis points expansion	approximately 19%	Shift to absolute margin target of ~19% (vs. prior expansion-based guidance); implies stronger profitability realization	Raised

Reaffirmed unchanged this quarter: Adjusted Diluted EPS Growth (+12% to 15% (excluding CoolIT impact))

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Global Water	$2.035B	+7.0%
Global Institutional & Specialty	$1.508B	+4.0%
Global Pest Elimination	$0.31B	+8.0%
Global Life Sciences	$0.201B	+11.0%
Global High-Tech Organic Growth	>20.0%	—
Life Sciences Bioprocessing Growth	>100.0%	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Organic Sales Growth	4.0%
Ecolab Digital Sales	$99 million
Ecolab Digital Growth	24.0%
Adjusted Operating Income Margin	16.7%
Adjusted Operating Income Growth	15.0%
Share Repurchases	1.3 million shares

Management tone

Commodity cost inflation has been reframed from headwind to strategic pricing opportunity. Three quarters ago, pricing was a defensive lever against input costs; two quarters ago it was migrating to baseline; this quarter management is using the 9% commodity inflation as the justification for an energy surcharge that accelerates pricing. From the call: "In 2022, commodities cost was up 50%... Today, commodities cost is up 9%, and we have all the tools to address this within one quarter, done the right way for our customers... we quickly implemented an energy surcharge." This is the third pricing-mechanism evolution in twelve months (3% target → trade surcharge → energy surcharge), and each iteration has been initiated by Ecolab rather than in reaction to peer moves. Pricing power is being demonstrated, not asserted.

High-Tech has completed its arc from "growth wave" rhetoric to integrated $1.5B AI infrastructure platform with quantified customer pull. Q2 FY2025 bucketed high-tech with growth engines; Q3 FY2025 called it a "structural growth wave"; Q4 FY2025 sized it at ~$1B; this quarter the CEO put a number on the post-acquisition footprint: "we're building a $1.5 billion powerhouse that will help fuel Ecolab's next phase of growth and margin expansion." The RBC exchange added concrete physics: Ovivo enables 95% water recycling in fabs (vs. 5% previously), 17 new fabs opening by 2030, and customers actively jumping the queue. CoolIT growing close to triple digits versus the 30%+ initial frame is the cleanest upside signal — management's deal-announcement assumptions are already conservative against actual demand.

Life Sciences has migrated from emerging growth vector to proven double-digit engine with margin runway. The Q1 +11% organic with bioprocessing >+100% is the inflection Seth Weber asked about being "the step change we've been waiting for" — and management confirmed it is. From the call: "Life sciences accelerated to 11% growth, led by bioprocessing, where sales more than doubled... we're just getting started." The China plant opening in H2 lifts the water-purification capacity constraint that was flagged on the Q2 FY2025 watch list and reaffirmed in Q3 FY2025. The combination of demand acceleration plus capacity unlocking in the same year is unusual.

Operating margin expansion has shifted from incremental execution to structural portfolio mix. Q4 FY2025 framing was a 100–150bps expansion bridge composed of gross margin plus OneEcolab. This quarter the framing is portfolio-shift driven: "this continues to shift our portfolio towards higher margin, higher growth, and markets well aligned with our long-term strategy." CoolIT and Ovivo are explicitly framed as high-margin with "low to no energy cost dependency" — meaning the FY26 commodity headwind doesn't apply to ~20%+ of post-acquisition revenue. The 2027 20% OI margin target now has an additional mechanical lever beyond OneEcolab.

Confidence-versus-macro framing inverted to 90/10 execution. Asked by Barclays about macro assumptions, management answered with precise numbers: 9% commodity inflation through year-end, 1% volume growth in H2, growth engines compounding at 12%. The "90% execution, 10% macro" framing — combined with explicit conservatism on volume (1%) while raising organic growth to 6–7% in H2 — implies management believes internal levers are doing the work and the macro is a residual.

Recurring themes management leaned on this quarter:

AI-driven demand for circular water and liquid cooling infrastructurePortfolio rotation toward higher-margin, higher-growth segments (Life Sciences, Global High-Tech)Energy cost volatility as pricing acceleration catalyst rather than margin headwindOneEcolab integration model driving operational leverage and customer stickinessCool IT and Ovivo acquisitions as catalysts for $1.5B high-tech powerhouseMission-critical service positioning enabling pricing power despite macro complexity

Risks management surfaced:

Middle East conflict driving sharply higher global energy costs and supply chain pressuresCommodity costs expected to remain high through end of yearShort-term EPS impact from Cool IT financing and non-cash amortization (~20 cents per quarter)Dynamic operating environment requiring ongoing complex global managementQ2 transitional period with single-digit commodity cost increases impacting EPS growth by few percentage points

Q&A highlights

Sam Kotz · Out4Tim

How does gross margin stabilization in H2 fit with the 20% OI margin goal in 2027, including impact of Cool IT acquisition?

Management expects gross margins to stabilize in H2 due to surcharge pricing implementation. Excluding Avivo, gross margin would improve 70-80 bps at traditional run rates. OI margin will be stronger due to SG&A leverage. Cool IT and Avivo are high-growth, high-margin businesses with low energy cost dependency, positioning the company well for 20% OI margin in 2027.

9% commodity cost inflation in Q2 expected to stay high through end of year5-6% pricing in H2 to stabilize margins70-80 bps underlying gross margin improvement excluding AvivoCool IT and Avivo represent 20%+ of company post-acquisition

Ronan Kennedy · Barclays

What is the macro scenario embedded in guidance? Does it assume stable demand or cautious customer posture given energy costs and geopolitical uncertainty?

Management states 90% of performance is driven by execution rather than macro. Assumptions are conservative: 9% commodity inflation Q2 through end of year, 1% volume growth expected in H2. Company is growing 5%+ ex-paper and heavy industries, with growth engines growing 12% at high margins. Focus is on controlling internal variables rather than macro predictions.

90% execution, 10% macro9% commodity inflation assumption through end of year1% volume growth assumed for H2Company growing 5%+ (ex-paper/heavy) with 6-7% organic growth target H2

Ashish Sabhadra · RBC

How is Ovivo tracking vs expectations? What are cross-sell opportunities with core offerings in high tech and potential with Cool IT?

Global high tech combining legacy business, Avivo, and Cool IT creates $1.5B business growing 20-25%+ at high margins. Avivo enables 95% water recycling in fabs (vs 5% previously), directly improving chip yields. Cool IT addresses data center water footprint. Both have higher backlogs than expected. Customers are seeking to jump queues due to supply constraints and competitive advantage.

Combined high tech business: $1.5B growing 20-25%+ with high marginsAvivo: 5% to 95% water recycling in microelectronics17 new fabs opening by 2030 (roughly one per month)Avivo mid-teens growth (longer cycle than Cool IT)

Jeff Sikaskis · J.P. Morgan

Can you quantify Cool IT growth rate beyond 30%? How does Cool IT compete in data center direct-to-chip markets—is competition chemistry or equipment-based?

Cool IT growing close to triple-digit range. Customers actively seeking to jump the queue; direct competitors (referenced as starting with 'V') also performing well. Cool IT offering is outcome-focused: higher uptime, lower water usage, better power performance. Business model is recurring through services, water treatment chemistry (3D Tracer), coolants, and equipment changes with each chip generation.

Cool IT growth close to triple-digit range (not 30%, 50%, 60%, or 70%)Customers competing to jump supply queueCompetitive offerings: equipment and chemistry both presentEcolab advantage: water treatment chemistry expertise + thermal management (80 years experience)

Seth Webber · BNP Paribas

Is life science's double-digit growth the step change we've been waiting for? How will margins expand once new capacity comes online?

Yes, 11% Q1 organic growth represents the expected performance inflection. Life science is building toward double-digit sustained growth and potentially faster. New capacity in H2 will unleash additional growth. Operating leverage targeting 30% long-term, with mid-20s expected mid-term as investments continue. Bioprocessing business grew north of 100% in Q1.

Life science Q1 organic growth: 11% (double-digit build)Bioprocessing growth: north of 100% in Q1New plant capacity opening H2 2024Operating margin target: 30% long-term

Answers to last quarter's watch list

Q1 FY2026 volume hitting +1% on exit. Not explicitly disclosed at +1% in the press release at quarter-exit granularity, but organic sales of +4.0% in Q1 combined with pricing in the 2–3% range implies volume contributed roughly 1–2pp — consistent with the exit commitment. Management's H2 framing assumes 1% volume growth, so the trajectory is intact even if the precise Q1-exit number wasn't broken out. Status: Resolved positively

Ovivo Electronics contribution disclosure. Resolved with the quantified $1.5B post-acquisition high-tech business framing and CoolIT-specific growth rate ("close to triple digits"). Combined high-tech growing 20–25%+; Ovivo specifically mid-teens (longer cycle than CoolIT); both with higher backlogs than expected. The AI-infrastructure narrative is no longer rhetorical — it has dollars, customer-pull evidence (queue-jumping), and a TAM mechanic (17 fabs by 2030). Status: Resolved positively

OneEcolab cadence through 2026. Not specifically called out on the print. Adjusted OI growth of +15% with operating margin +70bps YoY implies the SG&A leverage component is on track, but management didn't disclose an updated OneEcolab savings cadence number or signal a third upward revision this quarter. Status: Continue monitoring

Operating margin landing in the 18.9–19.3% FY2026 band. Q1 FY2026 adjusted OI margin came in at 16.7% — well below the 18.5% Q4 FY2025 benchmark referenced as a trajectory check. However, management explicitly reframed the FY target as "approximately 19%" absolute (vs. the prior expansion-based 18.9–19.3%), and the H2 acceleration math (5–6% pricing, commodity offset by Q2 exit) puts the back-half lift mechanically in scope. The Q1 print is the seasonal/commodity trough, not a derailment. Status: Continue monitoring

Water segment ex-paper growth holding at +5%. Global Water reported +7% (including Ovivo) — the underlying ex-paper, ex-Ovivo organic number wasn't separately disclosed on the press release. The +4% company-wide organic combined with management's "growing 5%+ ex-paper and heavy industries" comment in the Barclays exchange validates the thesis is intact at the company level. Segment-specific ex-paper water growth was not called out on the print. Status: Continue monitoring

What to watch into next quarter

Q2 FY2026 EPS landing above the $2.07 midpoint of the $2.02–$2.12 guide. With FY2026 guide reaffirmed at $8.43–$8.63 and Q1 actual of $1.70 plus Q2 midpoint of $2.07 implying H1 at ~$3.77, H2 needs ~$4.76 to hit midpoint — implying H2 EPS growth materially above the H1 pace. A Q2 print in the lower half of the range puts meaningful pressure on the FY band.

Energy surcharge fully offsetting commodity dollar impact by Q2 exit. Management committed to this on the call. Watch Q2 gross margin — if it doesn't begin to stabilize sequentially from Q1's 43.8%, the H2 6–7% organic acceleration thesis becomes harder to underwrite.

CoolIT regulatory approval and revenue contribution timing. Approval was referenced as Q3 expected. Watch for explicit revenue contribution disclosure and whether the close-to-triple-digit growth holds in Q2 as the comparison normalizes.

Organic growth bridging from 4.0% in Q1 to 6–7% in H2. This requires roughly 200–300bps of acceleration in two quarters. Watch Q2 organic — if it doesn't clear 5%, the H2 band requires Q3/Q4 to land at 6–8%, which leaves no room for execution slippage.

CoolIT EPS dilution disclosure. Management referenced ~$0.20/quarter EPS impact from CoolIT financing and amortization. Watch whether the FY guide is restated to include CoolIT impact — the current "$8.43–$8.63 excluding CoolIT" framing is unusual and will need reconciliation as the deal closes.

Sources

Ecolab Q1 FY2026 earnings press release, filed April 28, 2026 — https://www.sec.gov/Archives/edgar/data/31462/000110465926049822/ecl-20260428xex99d1.htm
Ecolab Q1 FY2026 earnings call Q&A and prepared management commentary (CoolIT growth "close to triple digits," $1.5B high-tech powerhouse framing, energy surcharge mechanics, FY guidance raise rationale)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.